Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

University of Warwick Wins Domainex’s First Discovery STAR Award

Published: Monday, September 02, 2013
Last Updated: Monday, September 02, 2013
Bookmark and Share
Domainex Ltd. has announced that the recipient of its first Discovery STAR Award; Professor Vilmos Fulop of the University of Warwick.

This award will give Professor Fulop access to Domainex’s outstanding drug discovery capabilities to support his research for a much-needed new treatment for Chagas disease - a potentially life-threatening disease.

 “Domainex received many strong applications to its Discovery STAR award scheme, but Professor Fulop’s project stood out as he had all the elements needed to start a drug discovery project in this area of unmet medical need,” said Eddy Littler, Chief Executive Officer of Domainex, “We very much look forward to helping Professor Fulop to identify inhibitors of his drug target, and hope that in doing so he will be able to access further funding that will support our joint efforts towards finding a new cure for this terrible disease.”

Domainex will provide Professor Fulop with expert drug discovery guidance and exclusive access to its unique LeadBuilder virtual hit screening technology. Following the identification of hits using this approach, Professor Fulop, who has been working with the University of Warwick’s innovation support team, Warwick Ventures, to take forward his research, will be looking for additional funding to progress his work to identify potential new drug candidates against Chagas disease.

Professor Vilmos Fulop of The University of Warwick said ‘I am absolutely delighted with this award and looking forward to working with Domainex. I regard this collaboration as a starting point towards making significant steps in the finding of a new cure for the treatment of neglected Chagas and the related African sleeping sickness disease.’

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ZoBio, Domainex Partner to support FORMA Therapeutics’ Drug Discovery Programs
ZoBio and Domainex Ltd. announce a collaboration with FORMA Therapeutics to provide NMR-based structural biology services for a substantial panel of FORMA drug targets.
Monday, December 08, 2014
Auspherix and Domainex Announce Collaboration
Collaboration to develop new drugs to treat antibiotic-resistant bacterial infections.
Wednesday, October 15, 2014
Domainex Researchers Identify Small-Molecule Inhibitors of TBK1/IKKepsilon Affecting IL-17 Signaling
Inhibitors may have utility in autoimmune disease treatment.
Monday, November 05, 2012
Domainex Lead Optimization Services Facilitate a new Cancer Drug Discovery Programme
The Company is now set to provide lead optimization services in collaboration with The Institute of Cancer Research.
Thursday, April 08, 2010
Domainex Ltd Wins Biotechnology Innovation Award
The award was presented by UK Trade & Investment for developing new technologies for streamlining and accelerating the drug discovery process.
Wednesday, August 22, 2007
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos